Dry Eye Disease: August 2026 Phase II/III Results for Novel Mechanisms

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/dry-eye-disease-august-2026-phase-ii-iii-results-for-novel-mechanismsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Dry Eye Disease: August 2026 Phase II/III Results for Novel Mechanisms Evidence cutoff: August 22, 2026 Introduction Dry eye disease treatment is moving beyond “replace the tears” with artificial tears. Newer therapies are attempting to stimulate the eye’s own tear reflex, restore the mucin layer, slow tear evaporation, improve meibomian gland function, or target inflammation in genetically selected patients. A date clarification is important: there was not one single August 2026 wave of completed Phase II or Phase III dry eye readouts covering all of these mechanisms. The most important recent human data available by August 22, 2026 include: The May 2026 publication of Phase III results for acoltremon, now marketed in the United States as Tryptyr. A 2026 randomized study of the mucin secretagogues diquafosol and rebamipide, showing effects within 30 minutes. A July 2026 randomized study of lipid-containing artificial tears in people with a thin tear-film lipid layer. Continuing Phase II/III programs for AZR-MD-001, licaminlimab, PL9643, and platelet-lysate biologics, for which definitive August 2026 efficacy results were not publicly posted. An August 8, 2026 publication involving troxipide nanoparticles applied through the eyelid was preclinical animal research, not a human Phase II or Phase III trial. It should not be interpreted as proof of clinical benefit in patients. Troxipide nanoparticle study () How to Interpret Dry Eye Trial Results Clinical trials usually measure both symptoms and signs: Symptoms Assessment iN Dry Eye, or SANDE, measures the frequency and severity of symptoms on a 0-to-100 scale. Higher scores indicate worse symptoms. Ocular Surface Disease Index, or OSDI, measures symptoms and their effect on daily activities. Higher scores indicate worse disease. Tear break-up time, often called TBUT, measures how long the tear film remains stable after a blink. A longer time is generally better. Corneal fluorescein staining measures damage to the surface cells of the cornea. A lower score is better. Schirmer testing estimates tear production using a paper strip. A larger increase suggests more aqueous tear production. These measures do not always improve together. A patient may have less burning but little change in staining, or may produce more tears without feeling much better. This symptom–sign mismatch is one of the major difficulties in dry eye research. Results also cannot be compared directly across studies unless the trial populations, control groups, dosing schedules, and measurement methods are similar. Summary of the Most Relevant 2026 Evidence For the full table, please open this article on visualfieldtest.com. Neurosensory Modulation: Acoltremon, or Tryptyr Mechanism and treatment concept Tryptyr contains acoltremon, a transient receptor potential melastatin 8 agonist. Transient receptor potential melastatin 8 channels are found on cold-sensitive sensory nerves in the cornea and eyelids. Activating these nerves can stimulate a reflex pathway involving the lacrimal gland and increase tear production. The mechanism is different from anti-inflammatory drugs such as cyclosporine and lifitegrast. It also differs from Miebo, which is designed primarily to reduce evaporation. The Food and Drug Administration review noted that acoltremon’s tear-producing effect is greatly reduced under topical anesthesia, supporting the importance of an intact sensory nerve pathway. Food and Drug Administration integrated review () Tryptyr was approved by the Food and Drug Administration on May 28, 2025, at a dose of one drop in each eye twice daily. Food and Drug Administration Drug Trials Snapshot for Tryptyr () Tear production The two pivotal Phase III studies, COMET-2 and COMET-3, enrolled a combined 931 patients. The primary endpoint was the percentage of patients achieving at least a 10-millimeter increase in unanesthetized Schirmer testing on day 14: COMET-2: 42.6% with acoltremon versus 8.2% with vehicle. COMET-3: 53.2% with acoltremon versus 14.4% with vehicle. Both differences were statistically significant. Increased tear production was also observed after the first dose and remained detectable through day 90 when the test was performed after dosing. Acoltremon Phase III publication Tryptyr prescribing information () Symptoms In COMET-2, the key secondary endpoint, change in the global SANDE score at day 28, favored acoltremon: Acoltremon: least-squares mean change of −19.7 points Vehicle: least-squares mean change of −14.7 points Difference: −5.1 points However, the same SANDE endpoint was not statistically significant in COMET-3, the replication study. The Food and Drug Administration also noted that day-90 symptom endpoints were not met and that the evidence for replicated symptom relief was weaker than the evidence for increased tear production. Food and Drug Administration review () Clinical interpretation: Tryptyr clearly stimulates tear production, but the size and consistency of symptom improvement may vary. It should not be presented as a guaranteed rapid pain-relief treatment for every patient. Corneal staining and tear-film stability The published Phase III report found greater reductions in total corneal fluorescein staining on days 28 and 90 and greater reductions in conjunctival staining across study visits. However, the regulatory approval was primarily based on the tear-production endpoint rather than a replicated symptom endpoint. Tear break-up time was measured in the trial program, but a replicated, clinically persuasive tear break-up time benefit was not the central basis for approval. The Food and Drug Administration review also raised uncertainty about how long the tear-stimulation effect lasts between the post-dose measurement and the next dose 12 hours later. () Onset of action Tryptyr appears to act very quickly on tear production: A significant effect was observed on day 1. The post-dose Schirmer test was started only a few minutes after instillation. The study does not prove that patients experience meaningful symptom relief within a few minutes. The duration of effect throughout the entire 12-hour dosing interval has not been clearly established. The practical expectation is therefore rapid stimulation of tearing, with symptom and surface improvements potentially requiring continued use. Safety and tolerability The main tolerability problem is burning or stinging immediately after use: Instillation-site pain occurred in approximately 50% of patients. Most events were mild. Less than 1% of patients discontinued treatment because of burning or stinging. No major drug-related safety signal was identified in the pivotal trials. Tryptyr is packaged in single-dose vials. One vial can be used for both eyes, but it must be discarded after use. Contact lenses should be removed before dosing and may be reinserted after 15 minutes. Tryptyr prescribing information () Likely responder phenotype The best mechanistic fit may be patients with: Low tear production. Preserved corneal sensory nerve function. A functioning reflex-tear pathway. Mixed disease with an aqueous-deficient component. This is a mechanism-based inference, not a validated clinical responder rule. The COMET trials did not establish that Tryptyr is superior in a clearly defined aqueous-deficient subgroup or inferior in evaporative disease. Patients with severe corneal nerve dysfunction, prominent neuropathic pain, or symptoms that are very poorly matched to clinical signs may respond unpredictably. Mucin Secretagogues: Diquafosol and Rebamipide Why mucin matters The tear film is not simply water. It includes: An aqueous component. A lipid component that reduces evaporation. A mucin component that helps tears spread across the ocular surface. The gel-forming mucin mucin 5AC, produced mainly by conjunctival goblet cells, helps lubricate the eye and maintain tear-film stability. 2026 randomized study A 2026 prospective paired-eye study compared 3% diquafosol with 2% rebamipide. This was not a large registration Phase III trial, but it provides unusually useful information about early pharmacologic effects. Thirty minutes after instillation: Both agents significantly increased tear mucin 5AC. Both improved symptoms and tear break-up time. The difference in tear break-up time between the two agents was not statistically significant. Diquafosol produced a greater improvement in the visual analog symptom score than rebamipide. Mucin 1, a membrane-associated mucin, did not change significantly during this short observation period. The study therefore supports a rapid tear-film and mucin effect, especially for patients with short tear break-up time or suspected mucin dysfunction. 2026 diquafosol and rebamipide study () Safety and tolerability Reported short-term symptoms were relatively common but generally mild: Burning was reported by approximately 20% of patients with diquafosol and rebamipide. Foreign-body sensation occurred in approximately 17% to 20%. Dryness was reported by approximately 13% with diquafosol and 23% with rebamipide. No significant tolerability difference was found between the treatments. Likely responder phenotype Mucin secretagogues may be most useful for patients with: Short tear break-up time. OcSupport the show